Jonathan Alexander Chatzkel

Author

University of Miami

Also Known As

Jonathan A Chatzkel, Jonathan A. Chatzkel, Jonathan Alexander Chatzkel, Jonathan Chatzkel

Publications

296

Citations

H-Index

Concepts

All Affiliations

University of Miami University of Florida Health Sylvester Comprehensive Cancer Center University of Florida University of Pennsylvania

About

Jonathan Alexander Chatzkel is an author at University of Miami specializing in medicine, tumor biology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	78
2	Pathology	2	2	32
3	Neurology	1	1	23
4	Pharmacology	1	1	23
5	Cancer Cell Biology	1	1	21

Jonathan Alexander Chatzkel

Publications

153

Citations

H-Index

Page 1

	Year	Citations
Expiratory Air Trapping on Thoracic Computed Tomography. A Diagnostic Subclassification Wallace T. Miller, Jonathan Alexander Chatzkel, Michael G. Hewitt Annals of the American Thoracic Society	2014	49
Red nucleus degeneration in hypertrophic olivary degeneration after pediatric posterior fossa tumor resection: use of susceptibility-weighted imaging (SWI) Arastoo Vossough, Pouya Ziai, Jonathan Alexander Chatzkel Pediatric Radiology Neuro-oncologyRed Nucleus DegenerationSusceptibility-weighted ImagingSurgeryHypertrophic Olivary Degeneration	2012	23
Metronidazole-induced cerebellar toxicity Jonathan Alexander Chatzkel, Arastoo Vossough Pediatric Radiology Metronidazole-induced Cerebellar ToxicityMedicineNeuropharmacologyToxicologyNeurology	2009	23
Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms. Thomas J. George, Ji‐Hyun Lee, Peter J. Hosein, Journal of Clinical Oncology Parp InhibitorCohort ABrca1-associated Protein 1PathologyCell Death	2022	21
Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer Jonathan Alexander Chatzkel, Michael J. Schell, Jad Chahoud, Clinical Genitourinary Cancer	2022	15
Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma Jonathan Alexander Chatzkel, James S. Lewis, Jessica Ley, Head and Neck Pathology Tumor ResponseTumor BiologyMedicinePathologyCancer Biology	2016	11
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms Thomas J. George, Ji‐Hyun Lee, David L. DeRemer, JCO Precision Oncology	2024	11

Page 1